Total Payments
$23,400
2024 Payments
$7,740
Companies
17
Transactions
43
Medicare Patients
5,140
Medicare Billing
$3.2M
Payment Breakdown by Category
Consulting$19,188 (82.0%)
Food & Beverage$2,225 (9.5%)
Travel$1,967 (8.4%)
Education$20.73 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $19,188 | 4 | 82.0% |
| Food and Beverage | $2,225 | 33 | 9.5% |
| Travel and Lodging | $1,967 | 5 | 8.4% |
| Education | $20.73 | 1 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Vital Art and Science, LLC | $12,673 | 2 | $0 (2018) |
| OnMark, Inc. | $4,940 | 1 | $0 (2024) |
| EyePoint Pharmaceuticals US, Inc. | $2,185 | 6 | $0 (2024) |
| Cardinal Health 108 LLC | $1,575 | 1 | $0 (2020) |
| Novartis Pharmaceuticals Corporation | $544.26 | 7 | $0 (2020) |
| Apellis Pharmaceuticals, Inc. | $453.43 | 5 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $267.60 | 7 | $0 (2024) |
| Regeneron Pharmaceuticals, Inc. | $195.14 | 2 | $0 (2024) |
| Alcon Laboratories Inc | $141.08 | 1 | $0 (2018) |
| BIOTISSUE HOLDINGS INC. | $135.96 | 2 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $7,740 | 18 | OnMark, Inc. ($4,940) |
| 2023 | $187.40 | 3 | Apellis Pharmaceuticals, Inc. ($122.83) |
| 2022 | $189.71 | 3 | Apellis Pharmaceuticals, Inc. ($151.81) |
| 2021 | $157.40 | 3 | Regeneron Pharmaceuticals, Inc. ($121.80) |
| 2020 | $1,850 | 5 | Cardinal Health 108 LLC ($1,575) |
| 2019 | $108.69 | 4 | Novartis Pharmaceuticals Corporation ($71.27) |
| 2018 | $7,979 | 5 | Vital Art and Science, LLC ($7,500) |
| 2017 | $5,188 | 2 | Vital Art and Science, LLC ($5,173) |
All Payment Transactions
43 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/05/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Food and Beverage | In-kind items and services | $115.20 | General |
| Category: Ophthalmology | ||||||
| 11/19/2024 | EyePoint Pharmaceuticals US, Inc. | EYP-1901 (Drug) | Travel and Lodging | Cash or cash equivalent | $57.88 | General |
| Category: Wet Age Related Macular Degeneration (wAMD) | ||||||
| 11/17/2024 | EyePoint Pharmaceuticals US, Inc. | EYP-1901 (Drug) | Travel and Lodging | In-kind items and services | $401.18 | General |
| Category: Wet Age Related Macular Degeneration (wAMD) | ||||||
| 11/17/2024 | EyePoint Pharmaceuticals US, Inc. | EYP-1901 (Drug) | Travel and Lodging | In-kind items and services | $401.18 | General |
| Category: Wet Age Related Macular Degeneration (wAMD) | ||||||
| 11/17/2024 | EyePoint Pharmaceuticals US, Inc. | EYP-1901 (Drug) | Travel and Lodging | In-kind items and services | $401.18 | General |
| Category: Wet Age Related Macular Degeneration (wAMD) | ||||||
| 11/16/2024 | EyePoint Pharmaceuticals US, Inc. | EYP-1901 (Drug) | Travel and Lodging | In-kind items and services | $705.28 | General |
| Category: Wet Age Related Macular Degeneration (wAMD) | ||||||
| 11/16/2024 | EyePoint Pharmaceuticals US, Inc. | EYP-1901 (Drug) | Food and Beverage | In-kind items and services | $218.68 | General |
| Category: Wet Age Related Macular Degeneration (wAMD) | ||||||
| 10/31/2024 | Regeneron Pharmaceuticals, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $73.34 | General |
| Category: OPHTHALMOLOGY | ||||||
| 10/30/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Food and Beverage | In-kind items and services | $63.59 | General |
| Category: Ophthalmology | ||||||
| 09/24/2024 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $91.19 | General |
| Category: EYE CARE | ||||||
| 09/03/2024 | Astellas Pharma US Inc | Izervay (Drug) | Food and Beverage | In-kind items and services | $25.25 | General |
| Category: Ophthalmology | ||||||
| 08/27/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological), EYLEA | Food and Beverage | In-kind items and services | $34.13 | General |
| Category: OPHTHALMOLOGY | ||||||
| 08/27/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Education | In-kind items and services | $20.73 | General |
| Category: OPHTHALMOLOGY | ||||||
| 07/12/2024 | OnMark, Inc. | — | Consulting Fee | Cash or cash equivalent | $4,940.00 | General |
| 07/02/2024 | Astellas Pharma US Inc | Izervay (Drug) | Food and Beverage | In-kind items and services | $22.73 | General |
| Category: Ophthalmology | ||||||
| 04/30/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $32.15 | General |
| Category: Immunology and Ophthalmology | ||||||
| 04/01/2024 | BIOTISSUE HOLDINGS INC. | — | Food and Beverage | In-kind items and services | $118.12 | General |
| 04/01/2024 | BIOTISSUE HOLDINGS INC. | — | Food and Beverage | In-kind items and services | $17.84 | General |
| 11/29/2023 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Food and Beverage | Cash or cash equivalent | $122.83 | General |
| Category: Ophthalmology | ||||||
| 11/14/2023 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $38.79 | General |
| Category: OPHTHALMOLOGY | ||||||
| 10/31/2023 | AbbVie Inc. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $25.78 | General |
| Category: EYE CARE | ||||||
| 12/07/2022 | Apellis Pharmaceuticals, Inc. | — | Food and Beverage | Cash or cash equivalent | $30.74 | General |
| 11/02/2022 | Apellis Pharmaceuticals, Inc. | — | Food and Beverage | Cash or cash equivalent | $121.07 | General |
| 01/10/2022 | Kala Pharmaceuticals, Inc. | INVELTYS (Drug), EYSUVIS | Food and Beverage | In-kind items and services | $37.90 | General |
| Category: Ocular | ||||||
| 12/07/2021 | Alcon Vision LLC | — | Food and Beverage | In-kind items and services | $14.00 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 11 | 1,447 | 7,504 | $4.0M | $1.1M |
| 2022 | 10 | 1,202 | 5,329 | $1.6M | $505,610 |
| 2021 | 9 | 1,250 | 5,701 | $1.7M | $678,329 |
| 2020 | 9 | 1,241 | 6,214 | $2.5M | $960,878 |
Total Patients
5,140
Total Services
24,748
Medicare Billing
$3.2M
Procedure Codes
39
All Medicare Procedures & Services
39 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | Office | 2023 | 107 | 1,001 | $2.2M | $679,531 | 31.1% |
| 67028 | Injection of drug into eye | Office | 2023 | 171 | 1,161 | $745,826 | $115,374 | 15.5% |
| 92014 | Established patient complete exam of visual system | Office | 2023 | 230 | 1,152 | $301,824 | $111,848 | 37.1% |
| J9035 | Injection, bevacizumab, 10 mg | Office | 2023 | 151 | 1,798 | $430,082 | $101,226 | 23.5% |
| 92134 | Imaging of retina | Office | 2023 | 294 | 1,416 | $227,976 | $44,475 | 19.5% |
| 92004 | New patient complete exam of visual system | Office | 2023 | 96 | 96 | $26,231 | $10,636 | 40.5% |
| 92202 | Extended exam of the back part of the eye with optic nerve drawing | Office | 2023 | 238 | 698 | $48,162 | $8,510 | 17.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 90 | 107 | $19,885 | $5,310 | 26.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 34 | 34 | $9,697 | $3,893 | 40.2% |
| 92012 | Established patient problem focused exam of visual system | Office | 2023 | 22 | 25 | $3,680 | $1,610 | 43.8% |
| 92201 | Extended exam of the back part of the eye with retinal drawing | Office | 2023 | 14 | 16 | $1,104 | $293.82 | 26.6% |
| J0178 | Injection, aflibercept, 1 mg | Office | 2022 | 22 | 285 | $555,750 | $203,725 | 36.7% |
| 67028 | Injection of drug into eye | Office | 2022 | 162 | 901 | $375,457 | $89,544 | 23.8% |
| J9035 | Injection, bevacizumab, 10 mg | Office | 2022 | 151 | 1,447 | $253,021 | $77,964 | 30.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 237 | 849 | $198,187 | $77,429 | 39.1% |
| 92134 | Imaging of retina | Office | 2022 | 264 | 1,043 | $123,995 | $31,314 | 25.3% |
| 92014 | Established patient complete exam of visual system | Office | 2022 | 78 | 111 | $28,936 | $11,010 | 38.0% |
| 92202 | Extended exam of the back part of the eye with optic nerve drawing | Office | 2022 | 216 | 620 | $37,154 | $7,381 | 19.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 42 | 42 | $12,691 | $5,222 | 41.1% |
| 92004 | New patient complete exam of visual system | Office | 2022 | 15 | 15 | $4,099 | $1,766 | 43.1% |
| 92201 | Extended exam of the back part of the eye with retinal drawing | Office | 2022 | 15 | 16 | $840.00 | $255.09 | 30.4% |
| J0178 | Injection, aflibercept, 1 mg | Office | 2021 | 38 | 474 | $924,300 | $349,635 | 37.8% |
| 67028 | Injection of drug into eye | Office | 2021 | 170 | 1,120 | $303,100 | $111,470 | 36.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 241 | 683 | $180,312 | $71,228 | 39.5% |
| J9035 | Injection, bevacizumab, 10 mg | Office | 2021 | 148 | 1,052 | $79,125 | $59,995 | 75.8% |
About Dr. Sai Chavala, M.D
Dr. Sai Chavala, M.D is a Retina Specialist healthcare provider based in Mount Pleasant, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/07/2007. The National Provider Identifier (NPI) number assigned to this provider is 1548391311.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Sai Chavala, M.D has received a total of $23,400 in payments from pharmaceutical and medical device companies, with $7,740 received in 2024. These payments were reported across 43 transactions from 17 companies. The most common payment nature is "Consulting Fee" ($19,188).
As a Medicare-enrolled provider, Chavala has provided services to 5,140 Medicare beneficiaries, totaling 24,748 services with total Medicare billing of $3.2M. Data is available for 4 years (2020–2023), covering 39 distinct procedure/service records.
Ad
Practice Information
- Specialty Retina Specialist
- Location Mount Pleasant, TX
- Active Since 03/07/2007
- Last Updated 01/16/2026
- Taxonomy Code 207WX0107X
- Entity Type Individual
- NPI Number 1548391311
Products in Payments
- mVT Home Vision Monitor (Device) $7,500
- mVT(R) Service (Device) $5,173
- EYP-1901 (Drug) $2,185
- Syfovre (Drug) $301.62
- EYLEA (Biological) $280.52
- EYLEA HD (Biological) $166.99
- Constellation (Device) $141.08
- BROLUCIZUMAB (Drug) $125.00
- OZURDEX (Drug) $116.97
- BEOVU (Drug) $78.63
- Izervay (Drug) $47.98
- INVELTYS (Drug) $37.90
- Vabysmo (Drug) $32.15
- XIIDRA (Drug) $23.54
- ForeseeHome (Device) $21.68
- EYLEA AFLIBERCEPT INJECTION (Biological) $15.23
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.